NCT06652048View on ClinicalTrials.gov

High-dose Furmonertinib or Combined with Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Furmonertinib 160mg QD

All patients enrolled into this group will receive furmonertinib 160mg p.o qd.

DRUG

Furmonertinib 240mg QD

All patients enrolled into this group will receive furmonertinib 240mg p.o qd.

DRUG

Furmonertinib 160mg QD plus Chemotherapy

All patients enrolled into this group will receive furmonertinib 160mg furmonertinib p.o qd plus chemotherapy\[(carboplatin AUC 5 / cisplatin 75mg/m2+ pemetrexed 500mg/m2) every 21 days ×4 cycles + pemetrexed 500mg/m2 every 21 days maintenance\]

All Listed Sponsors
lead

Jialei Wang

OTHER

NCT06652048 - High-dose Furmonertinib or Combined with Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | Biotech Hunter | Biotech Hunter